Clinical outcomes following stereotactic body radiation therapy (SBRT) for non-resectable pancreatic adenocarcinoma

Clinical outcomes following stereotactic body radiation therapy (SBRT) for non-resectable... J Radiat Oncol (2017) 6:279–286 DOI 10.1007/s13566-017-0313-8 ORIGINAL RESEARCH Clinical outcomes following stereotactic body radiation therapy (SBRT) for non-resectable pancreatic adenocarcinoma 1 1 1,2 Raj Singh & Hayden Ansinelli & Sanjeev Sharma Received: 4 April 2017 /Accepted: 3 May 2017 /Published online: 25 May 2017 Springer-Verlag Berlin Heidelberg 2017 Abstract associated with an increased risk of toxicity incidence Objectives The purpose of this study was to report on (5/9 patients vs. 3/51 patients; p =0.001). progression-free survival (PFS), overall survival (OS), and Conclusion SBRT was well-tolerated by PCa patients with related toxicities following stereotactic body radiation therapy fractionated SBRT trending towards superior PFS and less (SBRT) for non-resectable pancreatic cancer (PCa). toxicity as compared to single-fraction SBRT. Methods The RSSearch® Patient Registry was screened for . . PCa patients treated with SBRT. The relationship between Keywords Pancreatic adenocarcinoma Radiotherapy PFS, OS, and potential prognostic factors were evaluated SBRT Registry using the Kaplan-Meier method and continuous log-rank anal- ysis, and the correlation between treatment planning and tox- icity incidence was examined by logistic regression. Introduction Results Sixty patients met inclusion criteria. Twenty-three pa- tients (38.33%) had received adjuvant gemcitabine. Following Pancreatic cancer (PCa) is a major contributor to cancer-related SBRT, http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Journal of Radiation Oncology Springer Journals

Clinical outcomes following stereotactic body radiation therapy (SBRT) for non-resectable pancreatic adenocarcinoma

Loading next page...
 
/lp/springer_journal/clinical-outcomes-following-stereotactic-body-radiation-therapy-sbrt-BkX4h9IgAe
Publisher
Springer Berlin Heidelberg
Copyright
Copyright © 2017 by Springer-Verlag Berlin Heidelberg
Subject
Medicine & Public Health; Oncology; Imaging / Radiology; Cancer Research; Surgical Oncology; Surgery; Radiotherapy
ISSN
1948-7894
eISSN
1948-7908
D.O.I.
10.1007/s13566-017-0313-8
Publisher site
See Article on Publisher Site

Abstract

J Radiat Oncol (2017) 6:279–286 DOI 10.1007/s13566-017-0313-8 ORIGINAL RESEARCH Clinical outcomes following stereotactic body radiation therapy (SBRT) for non-resectable pancreatic adenocarcinoma 1 1 1,2 Raj Singh & Hayden Ansinelli & Sanjeev Sharma Received: 4 April 2017 /Accepted: 3 May 2017 /Published online: 25 May 2017 Springer-Verlag Berlin Heidelberg 2017 Abstract associated with an increased risk of toxicity incidence Objectives The purpose of this study was to report on (5/9 patients vs. 3/51 patients; p =0.001). progression-free survival (PFS), overall survival (OS), and Conclusion SBRT was well-tolerated by PCa patients with related toxicities following stereotactic body radiation therapy fractionated SBRT trending towards superior PFS and less (SBRT) for non-resectable pancreatic cancer (PCa). toxicity as compared to single-fraction SBRT. Methods The RSSearch® Patient Registry was screened for . . PCa patients treated with SBRT. The relationship between Keywords Pancreatic adenocarcinoma Radiotherapy PFS, OS, and potential prognostic factors were evaluated SBRT Registry using the Kaplan-Meier method and continuous log-rank anal- ysis, and the correlation between treatment planning and tox- icity incidence was examined by logistic regression. Introduction Results Sixty patients met inclusion criteria. Twenty-three pa- tients (38.33%) had received adjuvant gemcitabine. Following Pancreatic cancer (PCa) is a major contributor to cancer-related SBRT,

Journal

Journal of Radiation OncologySpringer Journals

Published: May 25, 2017

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off